anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Recent studies have uncovered that TIPE2 is involved in the development of cancer. However, less research has been conducted on the role of TIPE2 in melanoma. Our study aims to elucidate the mechanism of action of TIPE2 in the development of melanoma. We examined TIPE2 expression in paracarcinoma tissue and melanoma tissues and found that TIPE2 expression was downregulated in melanoma tissue compared with paracarcinoma tissue. Overexpression of TIPE2 significantly inhibited the proliferation of melanoma cells in vitro and even inhibited tumor formation in vivo. The CCK8 assay results indicated that TIPE2 overexpression suppressed the proliferation of melanoma cells. The colony-forming ability and wound healing ability of TIPE2-overexpressing melanoma cells were significantly reduced compared with those of control cells. Moreover, immunohistochemistry experiments using a nude mouse tumor model showed consistent results. TIPE2 inhibited the phosphorylation of MEK and ERK. In summary, TIPE2 suppresses the proliferation and migration of melanoma cells by affecting proliferation-related factors and possibly by regulating the MEK/ERK pathway. TIPE2 could be used to inhibit melanoma growth and is a potential drug target for future drug development.
Dermatofibrosarcoma protuberans (DFSP) is an aggressive tumour with multiple local recurrences and rare metastatic potential. Fibrosarcomatous transformation occurs in a few cases of DFSP which makes them more aggressive in terms of recurrence and metastasis. Here we report the case of a woman in her late 30s who presented with massive lower gastrointestinal (GI) bleeding with a history of multiple surgeries for DFSP on her anterior abdominal wall. The bleeding source was identified to be a mass lesion in the jejunum, which was excised. The patient recovered well and the histopathology revealed fibrosarcoma of the jejunum. Follow-up investigations showed multiple lung nodules, ascites and abdominal lymph nodes suggesting progressive disease. She is currently receiving chemotherapy and progressing well 3 months postoperatively. Patients with fibrosarcomatous changes within DFSP must be followed up closely as it is associated with increased metastatic potential.
FIELD: medicine.SUBSTANCE: group of inventions relates to a film-forming powder for forming a layer on a tooth surface, a method of producing such a powder and a granule based on such a powder. Disclosed is a film-forming powder for sputtering on the tooth surface to form a layer on the tooth surface for use in a sputtering device for a tooth with average particle size of 0.5 to 30 mcm. Film-forming powder is obtained by calcining apatite represented by formula Ca⋅M(ZO)Y, where X corresponds to value from 0 to 10; M represents an element selected from the group: sodium, lithium, magnesium, barium, strontium, zinc, cadmium, lead, vanadium, silicon, germanium, iron, arsenic, manganese, aluminium, rare-earth elements, cobalt, silver, chrome, antimony, tungsten and molybdenum, or hydrogen; ZOrepresents PO; Y is a hydroxyl group, a halogen element or a carbonate group, at temperature from 600 to 1350 °C with further exposure to plasma. Disclosed also is a method of producing a film-forming powder used in a sputtering device for tooth-spraying on a tooth surface to form a layer on the surface of the tooth with average particle size of 0.5 to 30 mcm, involving annealing said apatite, performed at temperature of 600 to 1350 °C, with subsequent grinding and sorting and subsequent exposure to plasma. To produce the powder, hydroxyapatite, which is the main component of the tooth, particularly hydroxyapatite with an admixture of a colour shade, can be used. Method may additionally include application of mechanical energy. Invention covers also tooth for sputtering on surface of tooth for formation of layer on surface of tooth for use in jet device for tooth containing said film-forming powder.EFFECT: use of the group of inventions allows forming a layer of high hardness and extremely low acid-solubility on the tooth surface over a short period of time by spraying said film-forming powder using a sputtering device.19 cl, 9 dwg, 82 tbl, 10 ex
<P>PROBLEM TO BE SOLVED: To provide a method for inducing a CTL (cytotoxic T lymphocyte) usable for treatment, etc., of intractable diseases such as cancer or viral infectious diseases and functioning specifically to disease antigens.  <P>SOLUTION: The method for inducing the CTL is carried out as follows. A cell line expressing at least MHC (major histocompatibility complex) class I and an co-stimulatory molecule is co-cultured with a lymphocyte after or while being brought into contact with a disease antigenic peptide. The CTL induced by the method is useful for, e.g. a drug for the cancer or infectious diseases and a therapeutic/prophylactic method therefor. A latent proliferation ability of the CTL can be tested according to the method for induction.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
All participants will be in this arm. Everyone will take all three different doses of iron-supplement (6mg; 30mg;60mg).
This group will receive exercise intervention in addition to their standard of care radiation treatment. At the baseline visit, they will meet with the certified exercise trainer (CET) and will be provided with a personalized exercise prescription and log to record what they do in between daily radiation treatment visits. The participant will also undergo an in-person exercise session prior to radiation therapy, which will take place either on the same day that the physical function tests are preformed or on a separate day. Participants will exercise between 1 and 7 times/week depending on the patient's tolerance to the exercise prescription. The CET will meet with the participant at every radiation treatment visit for an exercise counseling check-in. After five radiation treatments, the CET will follow-up with the participants via phone call once per week for 4 weeks during the follow-up period.
NEW MATERIAL:The compound of formulaI(R1 is H or phenyl; R2 is H, lower alkyl, or lower alkoxy; R3 is alkyl, cycloalkyl which may be substituted with lower alkyl, etc.) and its salt. EXAMPLE:1-(4-Aminobenzenesulfonyloxy)-2-pentanone. USE:Useful as an antilipemic agent, antiphlogistic agent, and immunoregulating agent. It has esterase-inhibiting and chymotrypsine-inhibiting activities. PROCESS:The compound of formulaIis prepared by reacting the alpha-haloketone of formula XCH2COR3 (X is halogen) with silver sulfonate of formula II in a solvent such as methanol, acetone, tetrahydrofuran, etc. at a temperature between room temperature and the boiling point of the solvent.
A total of 120 subjects will be randomized into three groups (30 per group). Arm A: IV PCIA Arm B: IV PCIA + ultrasound guided Erector spinae block (ESPB, Single shot of 30ml of 0.5% solution of Naropin \[Ropivacaine\]) Arm C: IV PCIA + multilevel intra-thoracic intercostal nerve block (ICB, Single shot of 30ml of 0.5% solution of Naropin \[Ropivacaine\]) PCIA pumps for all study cohorts will be programmed according to our institution's standard protocol (Dipidolor \[Piritramide\] bolus: 2mg, interval: 7 min, max 4h dose: 30mg). The erector spinae block will be placed preoperatively, the intercostal block will be placed at the beginning of the procedure. All patients will receive standard postoperative care. The patients will be blinded for the study arm.

The primary endpoint of this study is postoperative pain and will be recorded by using the numerical rating scale (NRS) pain score. Pain scores will be measured by the investigator at rest and during coughing. Opioid consumption will be monitored and registered for.
The primary goal is the adaptation, implementation and evaluation of a trauma and violence informed care (TVIC) intervention designed for Black women in middle Tennessee. In this 5-year RCMI project, the investigators propose 3 aims. Aim 1) Engage a stakeholder committee of patients, providers, and experts (COPE) to adapt a TVIC intervention for Black women and their healthcare providers at Meharry. \[Years 1-2\]. Aim 2) Implement and prospectively evaluate the adapted TVIC intervention at the healthcare provider-level, measuring changes in Meharry healthcare provider's self-efficacy for TVIC implementation and alignment with TIC knowledge, attitudes, and practices. \[Years 2-3\] Aim 3) Implement the adapted TVIC intervention at the patient-level to provide trauma-informed IPV screening, brief interventions, and referrals to treatment (SBIRT), and rigorously evaluate this TVIC intervention's impact on the primary outcome of patient-perceived usefulness of intervention and reported linkage to IPV services, and the secondary outcome of changes at the clinic-level relative to climate and culture, through a non-randomized pragmatic trial design. \[Year 4-5\].
Capturing circulating tumor cells (CTCs) from the peripheral blood of cancer patients, where they are disseminated among billions of other blood cells, is one of the most daunting challenge. We report OncoDiscover®, a multicomponent nano-system consisting of iron oxide (Fe3O4) nanoparticles (NPs), polyamidoamine generation 4 dendrimers (PAMAM-G4-NH2), graphene oxide (GO) sheets and an anti-epithelial cell adhesion molecule (anti-EpCAM) antibody (Fe-GSH-PAMAM-GO-EpCAM) for the selective and precise capture of CTCs. We further evaluated this system for therapeutically important oncotargets, exemplifying overexpression of the programmed death ligand 1 (PD-L1) as a functional assay on CTCs in cancer patients. We retrospectively evaluated 134 cancer patients for the presence of CTCs and 113 (84%) showed the presence of CTCs. About 62 (55%) of the CTC +ve patients showed CTCs with PD-L1 expression. The personalized cancer detection demonstrated by the OncoDiscover® CTC analysis tool is highly relevant for cancer monitoring and treatment outcomes.
Patients admitted with a clinical diagnosis of severe alcoholic hepatitis eligible to corticosteroid treatment. Prothrombin time at diagnosis was registered to evaluate wether it correlated with Lille score at day 7 and therefore response to standard medical treatment.
OBJECTIVE: It is expected that antioxidants contribute to slow the progression of chronic kidney disease (CKD). However, there are no data on the protective effect of dietary antioxidant vitamins on CKD. The purpose of study was to evaluate the renoprotective effect of dietary antioxidant vitamins in the general population.
DESIGN AND METHODS: The study participants were 127,081 Korean adults with preserved renal function with estimated glomerular filtration rate ≥60 mL/min/1.73 m2. They were categorized into 3 groups by tertile levels of dietary antioxidant vitamins intake including vitamins C, E, and A. Cox proportional hazard assumption was used to calculate multivariable hazard ratios and 95% confidence interval for the incident moderate to severe CKD (adjusted hazard ratio [95% confidence interval]) according to tertile levels of dietary intake of antioxidant vitamins. Subgroup analysis was conducted to evaluate the risk of progression from normal to mildly decreased renal function, and from mildly decreased renal function to moderate to severe CKD.
RESULTS: The risk of moderate to severe CKD was not significantly associated with the third tertile of dietary antioxidant vitamin intake including vitamin C (1.02 [0.78-1.34]), E (0.96 [0.73-1.27]), and A (0.98 [0.74-1.29]). Additionally, any tertile groups didn't show the significant association with the risk of moderate to severe CKD. Subgroup analysis also didn't show the decreased risk of progression from normal to mildly decreased renal function, and from mildly decreased renal function to moderate to severe CKD in any tertile groups.
CONCLUSION: Dietary intake of vitamins C, E, and A was not significantly associated with the risk of CKD progression.
Serotonin syndrome is an iatrogenic disorder induced by serotonergic drug. It is characterised by a symptomatic polymorphism that may create confusion with other clinical conditions, delaying diagnosis and putting the vital prognosis at risk. In light of a case report and a literature review, we here report the clinical case of a patient presenting with confusion, psychomotor agitation, hyperreflexia and spontaneous myoclonus following simultaneous use of paroxetine and amitriptyline. The diagnosis of serotonin syndrome was made after ruling out other possible diagnoses. The patient was admitted to the intensive care unit. This clinical case highlights the importance of thoroughly understanding the clinical manifestations of serotonin syndrome to ensure early and appropriate therapeutic management.
Reports of necrotizing fasciitis of the perineum (Fournier’s Gangrene), a rare but serious and life-threatening necrotizing infection requiring urgent surgical intervention, have been identified in postmarketing surveillance in patients with diabetes mellitus receiving SGLT2 inhibitors, including ertugliflozin. Cases have been reported in females and males. Serious outcomes have included hospitalization, multiple surgeries, and death.

Patients treated with SEGLUROMET presenting with pain or tenderness, erythema, or swelling in the genital or perineal area, along with fever or malaise, should be assessed for necrotizing fasciitis. If suspected, start treatment immediately with broad-spectrum antibiotics and, if necessary, surgical debridement. Discontinue SEGLUROMET, closely monitor blood glucose levels, and provide appropriate alternative therapy for glycemic control.
OBJECTIVE: To examine the efficacy, safety, and long-term durability of the autologous pubovaginal sling for stress incontinence over a 29-year period.
METHODS: A total of 192 consecutive female patients with stress urinary incontinence who underwent autologous pubovaginal sling from 1993 through 1999 were analyzed over a 29-year period. Intermediate and ultra long-term follow-up were obtained at a mean of 4 and 23 years, respectively. A total of 51 patients had sufficient data at both time intervals and were evaluated using a standardized questionnaire for resolution of stress incontinence, the primary endpoint, as well as resolution of urge incontinence, overall dryness, and voiding dysfunction.
RESULTS: At intermediate-term follow-up (mean 45.3 months), 96% of 51 patients reported no stress incontinence. In addition, 76% of patients experienced resolution of their preoperative urge incontinence. Overall dryness occurred in 84%. At ultra long-term follow-up (mean 22.9 years), 84% reported no stress incontinence and an overall dryness rate of 53%. Postoperative voiding dysfunction included de novo urge incontinence (3 patients) and persistent urinary obstruction requiring urethrolysis (1 patient).
CONCLUSION: The autologous pubovaginal sling is effective, safe, and durable at a mean of 23 years, the longest known follow-up in the literature. Given the U.S. Food and Drug Administration (FDA) warnings regarding transvaginal mesh and growing concerns with the synthetic midurethral sling, the autologous pubovaginal sling should be offered as an option to those women seeking treatment for stress urinary incontinence.
Some embodiments of the methods and compositions provided herein include preparing modified B cells. In some embodiments, the endogenous β -2 microglobulin (B2M) gene in the B cell is modified. Some embodiments relate to increasing resistance of modified B cells to allogeneic immune cell killing. In some embodiments, inactivation of the endogenous B2M gene increases resistance of the modified B cell to allogeneic immune cell killing. In some embodiments, insertion of a surrogate MHC-I into an inactivated endogenous B2M gene increases resistance of the modified B cell to killing by an allogeneic immune cell. Some embodiments include enriching for successfully modified cells.
Participants were administered panobinostat 20 milligram (mg) orally once a day (OD) three times a week as part of a 4 week (28 day) treatment cycle. Panobinostat were administered at the same time each morning with 8oz/240 milliliter (ml) of water after a fasting period of at least two hours (water was allowed). Participants could continue treatment until they experienced unacceptable toxicity or disease progression.
Non-automated neuromuscular blockade monitoring (TOF/PTC). As the NMB monitoring is depending on anesthesiologist usual practice and so only TOF measure is systematic, it is necessary to include a blind anesthesiologist measurement with the ATP mode in order to compare with data obtained during Time 2.
Among hospitalized patients worldwide, infections caused by multidrug-resistant (MDR) bacteria are a major cause of morbidity and mortality. This study aimed to isolate MDR bacteria from five intensive care units (ICUs) at Tripoli University Hospital (TUH). A prospective cross-sectional study was conducted over a seven-month period (September 2022 to March 2023) across five ICUs at TUH. A total of 197 swabs were collected from Patients', healthcare workers' and ICUs equipment. Samples collected from patients were nasal swabs, oral cavity swabs, hand swabs, sputum specimens, skin swabs, umbilical venous catheter swabs, and around cannula. Swabs collected from health care workers were nasal swabs, whereas ICUs equipment's samples were from endotracheal tubes, oxygen masks, and neonatal incubators. Identification and antimicrobial susceptibility test was confirmed by using MicroScan auto SCAN 4 (Beckman Coulter). The most frequent strains were Gram negative bacilli 113 (57.4%) with the predominance of Acinetobacter baumannii 50/113 (44%) followed by Klebsiella pneumoniae 44/113 (40%) and Pseudomonas aeruginosa 6/113 (5.3%). The total Gram positive bacterial strains isolated were 84 (42.6%), coagulase negative Staphylococci 55 (66%) with MDRs (89%) were the most common isolates followed by Staphylococcus aureus 15 (17.8%). Different antibiotics were used against these isolates; Gram- negative isolates showed high resistance rates to ceftazidime, gentamicin, amikacin and ertapenem. A. baumannii were the most frequent MDROs (94%), and the highest resistance rates in Gram-positive strains were observed toward ampicillin, oxacillin, ampicillin/sulbactam and Cefoxitin, representing 90% of total MDR Gram-positive isolates. ESBL and MRS were identified in most of strains. The prevalence of antibiotic resistance was high for both Gram negative and Gram positive isolates. This prevalence requires strict infection prevention and control intervention, continuous monitoring, implementation of effective antibiotic stewardship, immediate, concerted and collaborative action to monitor its prevalence and spread in the hospital.
The invention relates to a traditional Chinese medicine composition and application thereof. The raw material medicines of the traditional Chinese medicine composition comprise salvia miltiorrhiza, yam, astragalus, prepared monkshood, radix paeoniae alba, rhizoma corydalis and liquorice. The Chinese medicinal composition has the effect of treating rheumatoid arthritis. The traditional Chinese medicine composition disclosed by the invention is simple in raw materials, mainly comprises 7 raw materials such as salvia miltiorrhiza and liquorice, so that the number of the raw materials is greatly reduced, and the cost is saved. The traditional Chinese medicine composition has reasonable compatibility of raw material medicines and dosage thereof, and has good treatment effect on RA. It is comparable to MTX and LEF in improving clinical symptoms, signs, reducing ESR, CRP, RF, DAS28, etc. in treating RA. Meanwhile, the traditional Chinese medicine composition has less adverse reaction and good patient compliance.
FOCUS-EC provides developmental guidance, parent education, and key resilience skills that promote positive individual and family coping, including emotional regulation, problem solving, goal setting, communication, and management of deployment \& combat stress reminders, which foster parent-child and family cohesion. The intervention is delivered in six 90-minute sessions in the family home. Each session is structured with a check-in, review of the previous week's "home activity," primary activity and discussion, selection of a new "home activity", and a closing check-out. The family learns and practices the skills during the sessions, commits to practicing the skills during the week, and reports on their experiences the following session so that skills can be reinforced and adjustments made. FOCUS-EC promotes parenting skills and more cohesive family relationships in two key phases: 1) creating a family deployment and reintegration timeline and 2) enhancing parent-child interactions.
Metabolic reprogramming is a hallmark of cancer, enabling tumor cells to meet the high energy and biosynthetic demands required for their proliferation. High mobility group A1 (HMGA1) is a structural transcription factor and frequently overexpressed in human colorectal cancer (CRC). Here, we show that HMGA1 promotes CRC progression by driving lipid synthesis in a AOM/DSS-induced CRC mouse model. Using conditional knockout (Hmga1△IEC) and knock-in (Hmga1IEC-OE/+) mouse models, we demonstrate that HMGA1 enhances CRC cell proliferation and accelerates tumor development by upregulating fatty acid synthase (FASN). Mechanistically, HMGA1 increases the transcriptional activity of sterol regulatory element-binding protein 1 (SREBP1) on the FASN promoter, leading to increased lipid accumulation in intestinal epithelial cells. Moreover, a high-fat diet exacerbates CRC progression in Hmga1△IEC mice, while pharmacological inhibition of FASN by orlistat reduces tumor growth in Hmga1IEC-OE/+ mice. Our findings suggest that targeting lipid metabolism could offer a promising therapeutic strategy for CRC.
A process for modifying hydrated vegetable phosphatides comprises contacting them with a dilute aqueous acid to provide a mixture of pH 2-5, maintaining the resulting emulsion at an elevated temperature suitably 50-100 DEG  C. until it breaks and separating off the phosphatide-containing phase.  Suitable hydrated phosphatides are those obtained from soyabean oil, groundnut oil, rapeseed oil and sunflower oil. The acid used is suitably an aliphatic carboxylic acid such as formic-, acetic-, lactic- or citric-acid and is conveniently added as a 10% by weight aqueous solution at room temperature.  The phosphatide containing phase can be dried by heating at less than 80 DEG  C. under reduced pressure. The acidified phosphatides so produced may be brought to a pH of 6-7 with the aid of weak organic bases such as an ethanolamine, e.g. monoethanolamine before drying. The hydrated phosphatides may be obtained by treating a phosphatide-containing crude oil extract from plant with 0.5-10% by weight of water.  The products are suitable as emulsifiers in oil-water systems such as animal feeding stuffs, cooking fats, mayonnaise and mayonnaise like products.  Groundnut oil emulsions may also be stabilized by the addition of the modified phosphatides (see Division C1).ALSO:A groundnutoil-water emulsion is prepared by adding a modified plant phosphatide to the oil-water mixture at 50 DEG C and shaking, the phosphatide being one prepared by treating a hydrated plant phosphatide with dilute acid (see Division C2).  Other specified emulsions are animal feeding stuffs, cooking fats, mayonnaise and mayonnaise like products.